Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL

Jing Hua Huang, Song Nan Zhang, Kyung Ju Choi, Il Kyu Choi, Joo Hang Kim, Mingeol Lee, Hoguen Kim, Chae Ok Yun

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Recently, gene-based cytokine treatment has been actively pursued as a new promising approach in treating cancer. In an effort to augment the efficiency of antitumor effect by cytokine-mediated immunotherapy, we selected both interleukin (IL)-12 and 4-1BB ligand (4-1BBL) as suitable cytokines to fully activate the type-1 immune response. Coexpression of IL-12 and 4-1BBL mediated by oncolytic adenovirus (Ad) greatly enhanced the antitumor effect. Further, synergistic enhancement in interferon (IFN)-γ levels were seen in mice treated with oncolytic Ad expressing both IL-12 and 4-1BBL. Next, to improve the overall antitumor immune response, we coadministered IL-12-and 4-1BBL-coexpressing oncolytic Ad with dendritic cells (DCs). Combination treatment of IL-12-and 4-1BBL-coexpressing oncolytic Ad and DCs elicited greater antitumor and antimetastatic effects than either treatment alone. Moreover, enhanced type-1 antitumor immune response and higher migratory abilities of DCs in tumors were also observed in the combination arms. The nature of the enhanced antitumor immune response seems to be mediated through the enhanced cytolytic activity of cytotoxic T lymphocytes (CTLs) and IFN-γ-releasing immune cells. Taken together, these data highlight the potential therapeutic benefit of combining IL-12-and 4-1BBL-coexpressing oncolytic Ad with DCs and warrants further evaluation in the clinic.

Original languageEnglish
Pages (from-to)264-274
Number of pages11
JournalMolecular Therapy
Volume18
Issue number2
DOIs
Publication statusPublished - 2010 Jan 1

Fingerprint

4-1BB Ligand
Interleukin-12
Adenoviridae
Interleukin-4
Dendritic Cells
Immunity
Neoplasms
Cytokines
Therapeutics
Cytotoxic T-Lymphocytes
Immunotherapy
Interferons
Interferon-gamma

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Huang, Jing Hua ; Zhang, Song Nan ; Choi, Kyung Ju ; Choi, Il Kyu ; Kim, Joo Hang ; Lee, Mingeol ; Kim, Hoguen ; Yun, Chae Ok. / Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. In: Molecular Therapy. 2010 ; Vol. 18, No. 2. pp. 264-274.
@article{5192e15df8ed47b4ab3ad3e8d5d8a430,
title = "Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL",
abstract = "Recently, gene-based cytokine treatment has been actively pursued as a new promising approach in treating cancer. In an effort to augment the efficiency of antitumor effect by cytokine-mediated immunotherapy, we selected both interleukin (IL)-12 and 4-1BB ligand (4-1BBL) as suitable cytokines to fully activate the type-1 immune response. Coexpression of IL-12 and 4-1BBL mediated by oncolytic adenovirus (Ad) greatly enhanced the antitumor effect. Further, synergistic enhancement in interferon (IFN)-γ levels were seen in mice treated with oncolytic Ad expressing both IL-12 and 4-1BBL. Next, to improve the overall antitumor immune response, we coadministered IL-12-and 4-1BBL-coexpressing oncolytic Ad with dendritic cells (DCs). Combination treatment of IL-12-and 4-1BBL-coexpressing oncolytic Ad and DCs elicited greater antitumor and antimetastatic effects than either treatment alone. Moreover, enhanced type-1 antitumor immune response and higher migratory abilities of DCs in tumors were also observed in the combination arms. The nature of the enhanced antitumor immune response seems to be mediated through the enhanced cytolytic activity of cytotoxic T lymphocytes (CTLs) and IFN-γ-releasing immune cells. Taken together, these data highlight the potential therapeutic benefit of combining IL-12-and 4-1BBL-coexpressing oncolytic Ad with DCs and warrants further evaluation in the clinic.",
author = "Huang, {Jing Hua} and Zhang, {Song Nan} and Choi, {Kyung Ju} and Choi, {Il Kyu} and Kim, {Joo Hang} and Mingeol Lee and Hoguen Kim and Yun, {Chae Ok}",
year = "2010",
month = "1",
day = "1",
doi = "10.1038/mt.2009.205",
language = "English",
volume = "18",
pages = "264--274",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "2",

}

Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. / Huang, Jing Hua; Zhang, Song Nan; Choi, Kyung Ju; Choi, Il Kyu; Kim, Joo Hang; Lee, Mingeol; Kim, Hoguen; Yun, Chae Ok.

In: Molecular Therapy, Vol. 18, No. 2, 01.01.2010, p. 264-274.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL

AU - Huang, Jing Hua

AU - Zhang, Song Nan

AU - Choi, Kyung Ju

AU - Choi, Il Kyu

AU - Kim, Joo Hang

AU - Lee, Mingeol

AU - Kim, Hoguen

AU - Yun, Chae Ok

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Recently, gene-based cytokine treatment has been actively pursued as a new promising approach in treating cancer. In an effort to augment the efficiency of antitumor effect by cytokine-mediated immunotherapy, we selected both interleukin (IL)-12 and 4-1BB ligand (4-1BBL) as suitable cytokines to fully activate the type-1 immune response. Coexpression of IL-12 and 4-1BBL mediated by oncolytic adenovirus (Ad) greatly enhanced the antitumor effect. Further, synergistic enhancement in interferon (IFN)-γ levels were seen in mice treated with oncolytic Ad expressing both IL-12 and 4-1BBL. Next, to improve the overall antitumor immune response, we coadministered IL-12-and 4-1BBL-coexpressing oncolytic Ad with dendritic cells (DCs). Combination treatment of IL-12-and 4-1BBL-coexpressing oncolytic Ad and DCs elicited greater antitumor and antimetastatic effects than either treatment alone. Moreover, enhanced type-1 antitumor immune response and higher migratory abilities of DCs in tumors were also observed in the combination arms. The nature of the enhanced antitumor immune response seems to be mediated through the enhanced cytolytic activity of cytotoxic T lymphocytes (CTLs) and IFN-γ-releasing immune cells. Taken together, these data highlight the potential therapeutic benefit of combining IL-12-and 4-1BBL-coexpressing oncolytic Ad with DCs and warrants further evaluation in the clinic.

AB - Recently, gene-based cytokine treatment has been actively pursued as a new promising approach in treating cancer. In an effort to augment the efficiency of antitumor effect by cytokine-mediated immunotherapy, we selected both interleukin (IL)-12 and 4-1BB ligand (4-1BBL) as suitable cytokines to fully activate the type-1 immune response. Coexpression of IL-12 and 4-1BBL mediated by oncolytic adenovirus (Ad) greatly enhanced the antitumor effect. Further, synergistic enhancement in interferon (IFN)-γ levels were seen in mice treated with oncolytic Ad expressing both IL-12 and 4-1BBL. Next, to improve the overall antitumor immune response, we coadministered IL-12-and 4-1BBL-coexpressing oncolytic Ad with dendritic cells (DCs). Combination treatment of IL-12-and 4-1BBL-coexpressing oncolytic Ad and DCs elicited greater antitumor and antimetastatic effects than either treatment alone. Moreover, enhanced type-1 antitumor immune response and higher migratory abilities of DCs in tumors were also observed in the combination arms. The nature of the enhanced antitumor immune response seems to be mediated through the enhanced cytolytic activity of cytotoxic T lymphocytes (CTLs) and IFN-γ-releasing immune cells. Taken together, these data highlight the potential therapeutic benefit of combining IL-12-and 4-1BBL-coexpressing oncolytic Ad with DCs and warrants further evaluation in the clinic.

UR - http://www.scopus.com/inward/record.url?scp=76349109690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76349109690&partnerID=8YFLogxK

U2 - 10.1038/mt.2009.205

DO - 10.1038/mt.2009.205

M3 - Article

VL - 18

SP - 264

EP - 274

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 2

ER -